News for Agent

Daily business news: funding, M&A, launches

Partnerships

Abingdon Health and Centre for Process Innovation Sign MoU to Bridge MedTech Development Gap

By ·

Key takeaways

  • Abingdon Health signed a Memorandum of Understanding with Centre for Process Innovation to explore MedTech collaboration.
  • The agreement combines CPI's technology development expertise with Abingdon Health's manufacturing, regulatory and commercialisation services.
  • Both organisations hold ISO 13485-certified quality systems, which the companies said will simplify any transfer of programmes.

Abingdon Health plc signed a Memorandum of Understanding with Centre for Process Innovation to explore collaboration across the MedTech sector, the company announced on November 16, 2026. The announcement was published via Investegate.

How the Abingdon Health and CPI Agreement Works

Under the MoU, Centre for Process Innovation and Abingdon Health will identify opportunities where CPI can support innovators during early technology development, proof of concept, prototyping and process development. Programmes can then transition to Abingdon Health for product verification, validation, regulatory support and scalable manufacturing. Both organisations hold ISO 13485-certified quality systems, which the company said will simplify and accelerate any transfer.

The collaboration targets in vitro diagnostics, biosensors, wearable technologies, digital health solutions and next-generation medical devices. Abingdon Health said the MoU follows its recent expansion into the US and will further its ability to respond to demand for rapidly deployable diagnostic testing solutions.

Anthony Celli, Commercial Director of CPI, said: "The UK and US are home to world-class MedTech innovation, but many developers face challenges when moving from technology development to commercial manufacturing and regulatory approval." Chris Hand, Executive Chairman of Abingdon Health, said: "Through this partnership with CPI, we can engage with promising technologies earlier in their journey and provide a seamless route to product verification, regulatory approval and scalable manufacture."

Abingdon Health reported full-year revenue growth of almost a third and expects further progress in the current financial year despite short-term delays, Insidermedia reported on October 14, 2026.

CPI's Recent Partnership Record

According to akta.pro company records, CPI and Medicines Discovery Catapult launched a joint project in March 2026 to accelerate development of next-generation RNA medicines, extending CPI's RNA BioFoundry and RNA Training Academy investments. CPI also partnered with New Wave Biotech in October 2025 to enhance lipid extraction techniques using an AI-powered simulation platform, and with EnsiliTech in March 2025 on an Innovate UK-funded project to develop Ensilication technology that stabilizes antibodies at room temperature.

Other MedTech Manufacturing Agreements

Iconn Technologies, part of CAPE EMS, signed a three-year contract manufacturing agreement with Thermo Fisher Scientific effective August 2026, with up to two one-year extensions, EIN Presswire reported on November 13, 2026. EnPlusOne Biosciences and Nitto Denko Avecia signed an evaluation agreement to assess EnPlusOne's ezRNA platform for RNA therapeutic manufacturing, FinancialContent Business Page reported on November 5, 2026.

Companies in this story

Sources

Machine-readable: Markdown · JSON